Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
What is the mechanism of the true chronic effect of dietary polyphenols? (POLYTRUE?)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Advanced grants
Action type: Support for frontier research (ERC)
Panel: Applied life sciences and biotechnology
Countries involved: United Kingdom
Call:  (ERC-2012-ADG_20120314, 2012)
Start date: 2013-04-01
End date: 2018-03-31
Duration (months): 60.0
Total project cost (EUR): 2499065.0
EU funding (EUR): 2499065.0
Participants: 1
Project status: CLOSED

Although there have been many epidemiological and intervention studies on polyphenol-rich foods showing promising effects in reducing the risk of heart disease and diabetes, the true mechanisms of action remain elusive. In vitro systems to study nutritional mechanisms are limited by several factors and most have been derived from acute studies relevant to pharmaceutical research. In order to determine the chronic and true mechanisms of effects of dietary polyphenols that occur in the body as a result of diet, a paradigm shift in thinking is needed in the design of in vitro experiments. Based on human bioavailability data, I propose to develop suitable systems for the chronic study of polyphenols, and test these with the metabolites actually formed according to data from in vivo studies. The disparity between in vitro and in vivo studies will be bridged by the development of multi-cell type and engineered cells, overcoming some of the limitations of cell culture experiments. Based on these cells, chronic exposure to the main classes of polyphenols and metabolites, as found in blood, will be conducted using appropriate time scales and measuring relevant biomarkers. The groundbreaking nature will be to discover how polyphenols are actually working in the long term, more equivalent to lifetime exposure to foods. The experimental approach is designed to test the hypothesis that the exposure of cells to chronic low levels of metabolites, relevant to real nutrition, will have significant and different effects to those observed at acute high concentrations. This will finally provide the elusive explanation for the protective effects of polyphenol rich foods in epidemiological studies. The project involves a unique mixture of in vivo and in vitro experiments, the result of which will disconnect the inappropriate reliance of nutritional bioactive compound research on pharmaceutical thinking, and set the conduct of diet-relevant experiments on a new and more realistic path.

Keywords: polyphenol,metabolism
Intersecting hallmarks of cancer: mechanisms of and interplay between invasion and angiogenesis, guiding new strategies for cancer therapy (HALLMARKS-TO-THERAPY)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Advanced grants
Action type: Support for frontier research (ERC)
Panel: Physiology, Pathophysiology and Endocrinology
Countries involved: Switzerland
Call:  (ERC-2012-ADG_20120314, 2012)
Start date: 2013-09-01
End date: 2018-08-31
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: CLOSED

Acquisition of the hallmark capability for invasion and in turn metastasis is for most human cancers the defining event in progression to life threatening disease. Its determinants are remarkably complex. Genetically engineered mice can model human cancers, with tumors arising in specific organs, reflecting onco-genomic and histopathological features of particular tumor types. This project will use four mouse models to characterize newly implicated determinants of invasive tumor growth. We have observed that genetic polymorphisms can govern predisposition to invasive cancer. Additionally, therapeutic targeting of another hallmark capability – tumor angiogenesis – has revealed adaptive resistance, whereby late-stage tumors, faced with the inability to grow en masse supported by angiogenesis, switch instead to grow diffusively, by invading adjacent tissue; this phenomenon may underlay the limited benefit seen with anti-angiogenic therapies in the clinic. There are three interconnected goals: (1) Polymorphic regulation of tumor invasion. We will investigate the mechanisms and functional importance of candidate genes resident within a genetic modifier locus on mouse Chr 17 that can alternatively suppress or facilitate invasive tumor growth dependent on constitutional genetic background. (2) Adaptive induction of invasion. We will elucidate the determinants of the invasive growth capability that is induced in response to potent inhibition of angiogenesis. (3) Testing mechanism-based therapeutic co-targeting of the capabilities for invasion and angiogenesis. We will use functional genetic, genomic profiling, and pharmacological approaches to assess these two new modes of regulating invasive growth, and then apply the knowledge in preclinical trials aiming to lay the groundwork for future clinical trials in which these intersecting hallmark capabilities are coordinately disrupted, with promise for more enduring therapeutic responses and benefit to cancer patients.

Keywords: tumor invasion,mouse models of human cancer,preclinical trials of new cancer therapies,genetic predisposition to invasive cancers,melanoma,breast cancer,glioblastoma,panc. neuroendocrine tumor
Cytoplasmic terminal polymerases: small molecule opportunities to target the microRNA pathway. (TUTCHEM)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: United Kingdom
Call:  (ERC-2012-PoC, 2012)
Start date: 2012-11-01
End date: 2013-10-31
Duration (months): 12.0
Total project cost (EUR): 110946.0
EU funding (EUR): 98926.85
Participants: 1
Project status: CLOSED

MicroRNAs (miRNAs) are a novel class of human disease genes that are key to a number of therapeutic areas in particular cancer, and also heart disease, infectious disease and ageing. Specifically, some miRNAs are known to regulate cancer therapeutic targets acting as tumour suppressors and some are prognostic and diagnostic markers of human disease. The requirement for targeted anti-cancer therapies to effect specific disease treatment is well established and considered a primary goal for moving cancer towards a treatable, controllable chronic condition. miRNA-based therapeutics is a well-occupied space. However, existing commercial efforts and IP is focused on the use of oligonucleotides and oligonucleotide derivatives to inhibit or modulate the expression of miRNAs. Such efforts have been largely limited by the challenges associated with poor delivery. Instead we have identified novel opportunities to target miRNA pathways using small molecules. Specifically, we discovered a novel class of enzymes (TUTases) that regulate miRNAs by terminal polyuridylation. We found that a specific member of this family (Tut4) acts to inhibit the tumour suppressor miRNA let-7 in a model organism and human cancer cells. TUTases likely provide multiple novel anti-cancer targets. For example, the Tutase Gld2 was recently shown to regulate the p53 tumour suppressor pathway by modifying the miR-122 miRNA. We have developed an efficient in vitro assay of Tut4 activity. Here, we want to develop this assay into a high-throughput screening platform to identify small molecule inhibitors of Tutases. Such small molecules are proof-of-concept molecules for a novel anti-cancer strategy.

Keywords: 260688
PRE-industrial Photonic-based Radar dEsign (PREPARE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: Italy
Call:  (ERC-2012-PoC, 2012)
Start date: 2013-01-01
End date: 2013-12-31
Duration (months): 12.0
Total project cost (EUR): 166320.0
EU funding (EUR): 148300.0
Participants: 1
Project status: CLOSED

The aim of PREPaRE is the design and the IPR selling of a radically new pre-industrial photonics-based radar for industrial exploitation. It steps from the ERC project PHODIR which aim was to demonstrate the feasibility and advanced properties of the photonics-based radar. PREPaRE will focus on a specific application, the integrated traffic control (air-side and land-side) in airports, where the advances of photonics will be of practical interest in a short-medium term, and it will: i) study the technical and regulatory requirements and the current limitations, in order to define the required technical specifications; ii) accordingly modify and patent the PHODIR results, choosing the correct technological photonics solutions; iii) propose the patented pre-industrial design of each single subsystem to companies for encouraging an IP transfer through patent selling. Nowadays the air-side and land-size traffic control in airports needs several systems. PREPaRE will concentrate all the required functionalities in a single revolutionary radar system. Air-side traffic control will exploit simultaneously the required S and X bands for short and long range coverage. The land-side traffic (taxiing planes, vehicles, and persons) that currently is not controlled by radars to avoid interfering emissions, (complex video analysis is used instead), will be assured through a passive detection exploiting the reflected echoes of already present WiMax and DVBT sources, so that no further electro-magnetic pollution is generated. The team will collaborate with radar final users (local airports) for the specification definition, with radar system vendors for the radar market analysis, and with photonics components suppliers for the identification of the available mature technologies. The radar architecture has already gained the attention of a radar system vendor and of a company involved in data processing (see support letters), which could be interested in exploiting the related IPRs.

Keywords: 239640
Functional Biomarkers as in vitro diagnostic tools for managing patients with chronic disease (FUNCTIONALBIOMARKERS)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: France
Call:  (ERC-2012-PoC, 2012)
Start date: 2013-02-01
End date: 2014-01-31
Duration (months): 12.0
Total project cost (EUR): 163585.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

The aim of this proposal is to establish a business plan for the development of a new class of Functional Biomarkers as in vitro diagnostic tools for managing patients with chronic disease. The proof of concept will be established by focusing on substrates of the X-prolyl dipeptidylpeptidases (DPP), a family of pleotropic enzymes that cleave the N-terminal two amino acids of proteins. There are >30 known substrates for DPPIV, the best characterized member of this family. Importantly the catalytic activity of DPPIV results in the conversion of agonist ligands into antagonist or non-functional proteins. In the context of our funded ERC project, we have provided the first in vivo evidence of DPPIV-mediated cleavage of the chemokine interferon-induced protein 10 (IP-10 or CXCL10) [Casrouge, JCI 2011]. These initial observations have recently been validated, conclusively demonstrating the ability to predict treatment failure in chronic HCV patients (p-value <0.001 for antagonist CXCL10 and negative predictive value = 93.5%). Based on the important role of DDPIV in disease pathogenesis and following from our findings, there are two ideas that we wish to develop further as proof of concept for ‘Functional Biomarkers’ in the management of patients. First, we wish to evaluate the market needs for developing a privately run SME, aimed at providing theragnostic testing useful for stratification of chronic HCV patients. We will also examine the potential value of applying these in vitro diagnostic (IVD) tools in other disease settings in which DPPIV and/or CXCL10 have been identified as a predictive biomarker. Second, we aim to extend our repertoire of assays to include other disease relevant DPPIV substrates.

Keywords: 220850
STEM-TECH: Introducing proprietary stem cell marker technology for the life sciences market (STEM-TECH)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: Netherlands
Call:  (ERC-2012-PoC, 2012)
Start date: 2013-02-01
End date: 2014-07-31
Duration (months): 18.0
Total project cost (EUR): 163100.0
EU funding (EUR): 148280.0
Participants: 1
Project status: CLOSED

STEM-TECH has been designed to investigate the commercial opportunity for exploiting our patented stem cell marker technology in the life sciences market. This proprietary technology will meet the need for new enabling technologies that unlock the potential of stem cell detection in academic, industrial and clinical research and practice. THE OPPORTUNITY The stem cell market is a relatively immature market with an estimated size of around EUR 1 billion in 2011. It is expected that the market for stem cell technologies will increase substantially, mainly because leading biopharmaceutical companies are showing considerable interest in this area. Next to the pharma industry, major suppliers and small companies are now developing a wide range of stem cell approaches, which reflects the interest in this emerging area. Companies like Invitrogen provide reagents and services for stem cell research. THE PROJECT In STEM-TECH the central aim is to commercialise a (cancer) stem cell detection technology that can be used in intestinal, skin, breast and brain (cancer) stem cell research for (not exhaustive): - Fundamental and applied research purposes, e.g. the study of stem cell behaviour or signaling in and ex vivo; - The development of clinical detection methods (diagnostics) for determining disease status and metastasis; - The development of treatments that are specifically targeted at cancer stem cells. THE FINAL GOAL In a 12 month project, the skilled team of STEM-TECH will analyse the business potential of the proprietary stem cell marker technology. Within this project we will validate the technology to increase value, conduct a detailed market research, file and define the IP stratetgy and develop a full fledged business plan. The path that results in the highest ratio of return over effort will be used for commercialization.

Keywords: 242958
Production and Reliability Oriented SOFC Cell and Stack Design (PROSOFC)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Fuel Cells and Hydrogen
Action type: Collaborative project
Partnership: FCH (Art-185)
Countries involved: Austria,Denmark,Germany,Germany,United Kingdom,European organisations area,Austria
Call:  (FCH-JU-2012-1, 2012)
Start date: 2013-05-01
End date: 2017-10-31
Duration (months): 54.0
Total project cost (EUR): 7331214.71
EU funding (EUR): 3011000.0
Participants: 10
Project status: CLOSED

This project aims at improving the robustness, manufacturability, efficiency and cost of SOLIDpower’s state-of-the-art SOFC stacks so as to reach market entry requirements. We propose a focused project addressing the key issues that have manifested themselves in the course of the ongoing product development efforts at SOLIDpower SA. The key issues are the mechanical robustness of solid oxide fuel cells (SOFCs), and the delicate interplay between material properties, stack design, and operating conditions of the SOFC stack. The novelty of the project lies in combining state of the art methodologies for cost-optimal reliability-based design (COPRD) with actual production optimization. To achieve the COPRD beyond state of the art multi-physical modelling concepts must be developed and validated for significantly improved understanding of the production and operation of SOFC stacks. The key to this understanding is validating experiments and models on multiple levels of the SOFC system and introduction of extensive test programs specified by the COPRD methodology.

Keywords: cell and stack manufacturing,modelling,failure modes,probabilistic simulation,failure probability,stack testing,post mortem analysis,sofc,cell material parameters,reliability targets
ALKAMMONIA: Ammonia-fuelled alkaline fuel cells for remote power applications. (ALKAMMONIA)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Fuel Cells and Hydrogen
Action type: Collaborative project
Partnership: FCH (Art-185)
Countries involved: United Kingdom,Germany,Switzerland,Italy,Germany,United Kingdom
Call:  (FCH-JU-2012-1, 2012)
Start date: 2013-05-01
End date: 2018-06-30
Duration (months): 62.0
Total project cost (EUR): 2884512.59
EU funding (EUR): 1962548.0
Participants: 8
Project status: CLOSED

In project ALKAMMONIA a proof-of-concept system designed to provide power in remote applications will be developed and tested. The project will integrate three innovative and proven technologies: a highly efficient and low-cost alkaline fuel cell system, and a novel ammonia fuel system which consists of a fuel delivery system and a cracker system for generation of a hydrogen rich gas. The integrated system will be rigorously tested and the results will be shared with leading telecommunication end-users. A high proportion (> 75%) of the financial request would be spent on personnel costs, creating highly skilled permanent jobs in the European clean energy sector. The consortium is comprised of global leaders in the fields of alkaline fuel cell development, fuel cell system integration, fuel cell certification, ammonia cracking technology and energy technology assessment. The fuel cell and fuel processing technologies that are combined in project ALKAMMONIA have both demonstrated excellence at laboratory test level. The consortium is ideally suited to combine the three technologies and deliver a working proof-of-concept system that will demonstrate its potentially commercial viability in highly lucrative target markets.

Keywords: alkaline fuel cells,ammonia cracker,remote power,solid-state fuel,power system,telecommunications,base transceiver stations
Flexible Application of Uncertainty for Scanning and Tracking (F.A.U.S.T.)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Intra-European Fellowships
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom
Call:  (FP7-PEOPLE-2012-IEF, 2012)
Start date: 2013-05-01
End date: 2015-04-30
Duration (months): 24.0
Total project cost (EUR): 231283.2
EU funding (EUR): 231283.2
Participants: 1
Project status: CLOSED

F.A.U.S.T. -- "Flexible Application of Uncertainty for Scanning and Tracking" proposes to integrate uncertainty information about medical image processing methods completely into the clinical work flow. This requires to solve computational problems that arise when different algorithms try to monopolize the available hardware. These problems becomes even more demanding for algorithms that are accelerated by Graphics Processing Units (GPUs). To overcome the current shortcomings of recent programming methods for GPUs, the fellow will use a novel GPU-accelerated framework, which he has developed during his previous career together with his colleagues form Graz University of Technology as a base. During the proposed project, the fellow will first adapt this framework to make scheduled and prioritized execution of GPU-accelerated medical segmentation and registration algorithms feasible, subsequently apply and evaluate this framework for existing algorithms and further develop a concurrent real-time visualization of uncertainties, which are currently neglected during medical standard procedures. To proof the flexibility and applicability of the proposed methods, the fellow will finally develop a novel Magnetic Resonance Imaging (MRI) scanner steering method, which is based on uncertainty information and which will allow to evaluate the organs of a moving foetus within the uterus. In contrast to Ultrasound-based imaging, the proposed new method will allow an earlier and more accurate diagnosis of malformations and foetal diseases and will enable treatments in time. Thereby, the fellow will draw on his rich experience with GPU accelerated three-dimensional and four-dimensional medical volume processing and will provide unseen interactive results in the course of F.A.U.S.T..

Keywords: g104 graphics and image processing,g314 medical engineering and technology,g113 parallel and distributed computing,g115 systems and software
Design and Implementation of a Load Simulator Rig and Ground Test Bench Adaptation Kit for a HEMAS Test Rig (TESTHEMAS)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Clean Sky
Action type: Article 171 of the Treaty
Partnership: CLEAN-SKY (Art-185)
Countries involved: Spain
Call:  (SP1-JTI-CS-2012-02, 2012)
Start date: 2013-04-01
End date: 2016-03-31
Duration (months): 36.0
Total project cost (EUR): 911120.0
EU funding (EUR): 683340.0
Participants: 1
Project status: CLOSED

The TESTHEMAS project will design, manufacture and tune an innovative and smart Test Rig for linear actuators that will be capable of conducting synchronized tests on three assemblies of Helicopter linear Electro Mechanical Actuators (HEMAS) while applying different counterloads on them. This functionality will be controlled and monitored by means of a local control, command and data monitoring system. On the other hand, the test rig will incorporate an adaptation kit able to be inserted in a global test bench simulating an aircraft network called Electrical test Bench (Copper Bird) in such a way that the test rig can be operated remotely including a very versatile data transfer capacity This actuator test rig will be based on a modular, eco-efficient and adaptive concept by integrating easily exchangeable hydraulic and mechanical components with sensors and control strategies that will allow automatic and autonomous safe operation that will assure optimised lifecycle costs and environmental impacts during HEMAS tests. This innovative concept of actuator test bench will mean thus a positive impact on the safety and working conditions of the end users of the Test Bench as well as a reduction in the time and costs associated to testing linear actuators together with an increase in the quality and reliability of said tests. The TESTHEMAS system will be tested and validated at several stages: Virtual validation at model level and final experimental validations of the complete system. These sequential and complementary validations will assure thus a reliable, safe and efficient performance of the prototype and will provide data for a deep concept evaluation.

Keywords: electro mechanical actuator,test bench,test rig,aero,copper bird,load simulator,counterload,adaptation kit